ELCC 2023 | Practical considerations for the use of liquid biopsies in lung cancer

Klaus Pantel, MD, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, Germany, discusses whether circulating tumor DNA (ctDNA) fragment analysis is redundant or complementary in patients that harbor a drugable mutation such as PD-L1. Dr Pantel also comments on the advancement of novel approaches examining extracellular vesicle components as indicators of the disease status in patients with lung cancer. This interview took place at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.